Mesa Laboratories (NASDAQ:MLAB) Shares Gap Up to $128.90

Mesa Laboratories, Inc. (NASDAQ:MLAB)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $128.90, but opened at $135.84. Mesa Laboratories shares last traded at $135.84, with a volume of 2,624 shares.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI increased their target price on Mesa Laboratories from $106.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday, August 6th.

Mesa Laboratories Price Performance

The firm has a market capitalization of $735.08 million, a P/E ratio of -2.73 and a beta of 0.86. The stock’s fifty day simple moving average is $106.13 and its 200 day simple moving average is $106.00. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.37 and a quick ratio of 1.86.

Mesa Laboratories (NASDAQ:MLAB) last posted its earnings results on Wednesday, June 5th. The medical instruments supplier reported $2.25 EPS for the quarter. Mesa Laboratories had a negative net margin of 117.61% and a positive return on equity of 10.10%. The company had revenue of $58.90 million during the quarter. On average, equities research analysts predict that Mesa Laboratories, Inc. will post 6.91 EPS for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Friday, August 30th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a yield of 0.47%. The ex-dividend date is Friday, August 30th. Mesa Laboratories’s dividend payout ratio is currently -1.36%.

Institutional Trading of Mesa Laboratories

A number of institutional investors have recently bought and sold shares of the stock. King Luther Capital Management Corp lifted its stake in shares of Mesa Laboratories by 100.0% during the fourth quarter. King Luther Capital Management Corp now owns 27,781 shares of the medical instruments supplier’s stock worth $2,911,000 after buying an additional 13,890 shares during the period. Boone Capital Management LLC acquired a new position in shares of Mesa Laboratories in the fourth quarter valued at about $6,712,000. Vanguard Group Inc. raised its stake in shares of Mesa Laboratories by 0.8% in the first quarter. Vanguard Group Inc. now owns 373,397 shares of the medical instruments supplier’s stock worth $40,973,000 after purchasing an additional 3,119 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Mesa Laboratories by 515.6% during the fourth quarter. Quadrant Capital Group LLC now owns 277 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 232 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new stake in Mesa Laboratories in the first quarter valued at approximately $605,000. 90.60% of the stock is currently owned by institutional investors and hedge funds.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.